Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;39(3):256-262.
doi: 10.1111/phpp.12833. Epub 2022 Sep 13.

Efficacy of ultraviolet A1 phototherapy for inflammatory, sclerotic and neoplastic dermatological diseases: A 10-year tertiary referral center experience

Shachar Ronen  1 , Yuval Ramot  1   2 , Abraham Zlotogorski  1   2 , Rony Shreberk-Hassidim  1   2
Affiliations

Efficacy of ultraviolet A1 phototherapy for inflammatory, sclerotic and neoplastic dermatological diseases: A 10-year tertiary referral center experience

Shachar Ronen et al. Photodermatol Photoimmunol Photomed. 2023 May.

Abstract

Background: Ultraviolet (UV) A1 phototherapy is considered a beneficial treatment for various inflammatory, sclerotic, malignant, and other skin conditions. However, the available data regarding its efficacy for different indications, the potential side effects, and the recommended treatment protocols are sparse.

Objectives: To assess the efficacy of UVA1 phototherapy and identify correlation between different indications and treatment protocols to response rates.

Methods: We performed a retrospective study of a cohort of 335 patients treated with UVA1 phototherapy at the Department of Dermatology at Hadassah Medical Center, Jerusalem, Israel, between 2008 and 2018.

Results: The study population included 163 patients with inflammatory diseases (mainly atopic dermatitis and other types of eczema), 67 patients with sclerotic diseases (morphea and graft versus host disease), nine patients with neoplastic diseases (cutaneous T cell lymphoma), and 188 patients with other cutaneous disorders. Response rates ranged between 85% and 89% across indications, without differences in response rates among the indication groups (p = .941). In a multivariant logistic regression model, increased number of treatments and higher maximal dosages were associated with response to treatment (p < .001). Using ROC analysis, a cut-off of 8 UVA1 phototherapy treatments was chosen as predictive for beneficial response (86.4% sensitivity, 78% specificity). A cut-off of 40 J/cm2 was chosen as an optimal maximal dosage for differentiating between responders and non-responders (51.1% sensitivity, 83.1% specificity).

Conclusions: UVA1 phototherapy is an effective treatment for a variety of skin conditions. In most patients, at least eight treatments of a medium-high dosage are required for clinical response.

Keywords: atopic dermatitis; cutaneous T cell lymphoma; inflammatory; morphea; neoplastic; phototherapy; sclerotic; ultraviolet A1.

PubMed Disclaimer

References

REFERENCES

    1. Vangipuram R, Feldman SR. Ultraviolet phototherapy for cutaneous diseases: a concise review. Oral Dis. 2016;22:253-259.
    1. Lim HW, Silpa-Archa N, Amadi U, Menter A, Van Voorhees AS, Lebwohl M. Phototherapy in dermatology: a call for action. J Am Acad Dermatol. 2015;72:1078-1080.
    1. York NR, Jacobe HT. UVA1 phototherapy: a review of mechanism and therapeutic application: UVA1 phototherapy. Int J Dermatol. 2010;49:623-630.
    1. Gambichler T, Terras S, Kreuter A. Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: facts and controversies. Clin Dermatol. 2013;31:438-454.
    1. Kerr AC, Ferguson J, Attili SK, et al. Ultraviolet A1 phototherapy: a British Photodermatology Group workshop report: BPG UVA1 workshop report. Clin Exp Dermatol. 2012;37:219-226.

LinkOut - more resources